Nanopharmaceutical companies operate at the intersection of nanotechnology and pharmaceuticals, focusing on innovative drug delivery and formulation methods. By leveraging nanomaterials, these companies aim to enhance the effectiveness and reduce side effects of therapies. The industry is witnessing advancements in targeted therapies, especially in oncology and genomics. As more momentum builds in personalized medicine, techniques like lipid nanoparticle formulations are proving vital, especially highlighted during the COVID-19 vaccine response. Furthermore, the rising demand for advanced therapeutic agents opens avenues for nano-sized platforms, creating a shift towards improved patient outcomes and cutting-edge treatments.


The companies in this list represent a mix of sizes, ranging from small startups to more established firms, primarily based in North America and Europe. Founded between 2001 and 2022, these firms specialize in various areas, including drug delivery systems, biopharmaceuticals, and cancer therapies. Many operate through private ownership, while others secure venture capital to fuel their growth. Their innovative products utilize nanotechnology to improve therapeutic efficacy and safety, addressing crucial health issues.


Top 24 Nanopharmaceuticals Companies


1. Precision NanoSystems is now part of Cytiva


Precision NanoSystems, now part of Cytiva, is a biotechnology firm based in Vancouver, British Columbia, Canada. Founded in 2010, the company specializes in lipid nanoparticle technologies that are crucial for the development of genomic medicines, including mRNA vaccines and therapeutics. They offer a range of services from formulation development to cGMP manufacturing, primarily targeting biopharmaceutical companies involved in drug development for various diseases. Their innovative NanoAssemblr technology facilitates the efficient production of lipid nanoparticles, which are essential for delivering nucleic acid medicines. Precision NanoSystems has been instrumental in advancing the field of genomic medicine, particularly in the wake of the COVID-19 pandemic, where their technologies have been utilized to accelerate vaccine development. Their commitment to enhancing the efficacy and safety of drug delivery systems positions them as a significant player in the nanopharmaceutical industry.


2. Nanovex Biotechnologies


Nanovex Biotechnologies is a private biotechnology company based in Honduras, founded in 2014. With a team of approximately 23 employees, the company focuses on developing advanced drug delivery systems utilizing nanotechnology. Their product offerings include liposomes and synthetic exosomes, which are designed to improve the efficacy and safety of pharmaceuticals. By addressing challenges such as low efficacy, toxicity, and poor bioavailability, Nanovex aims to enhance the therapeutic potential of various compounds. The company also extends its expertise to the cosmetic industry, adapting its drug delivery technologies for cosmetic applications. This dual focus allows them to cater to a wide range of clients, from pharmaceutical developers to cosmetic manufacturers. In 2019, Nanovex received a grant of €81,868, which underscores their ongoing commitment to innovation and research in the field.


3. Apurano Pharmaceuticals GmbH


Apurano Pharmaceuticals GmbH, founded in 2014 and based in Warngau, Bavaria, Germany, is a private pharmaceutical and biotechnology company. With a team of 24 employees, Apurano is dedicated to the development of smart bio-nanotechnology solutions. The company focuses on creating innovative nanotechnology products that aim to improve drug delivery mechanisms and enhance therapeutic efficacy. Their work is particularly relevant for healthcare providers and researchers who seek advanced solutions in drug administration. Apurano's commitment to this specialized area of pharmaceuticals positions it as a noteworthy player in the nanopharmaceutical sector, contributing to the ongoing evolution of drug delivery systems.


4. nanoComposix | Fortis Life Sciences

  • Website: nanocomposix.com
  • Ownership type: Private Equity
  • Headquarters: San Diego, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: July 2021
  • Founded year: 2004
  • Headcount: 51-200
  • LinkedIn: nanocomposix

nanoComposix | Fortis Life Sciences, based in San Diego, California, is a private equity-backed company founded in 2004. The firm specializes in the production and customization of nanoparticles, catering to the biotechnology and pharmaceutical sectors. Their offerings include a wide range of nanoparticles such as gold, silver, and silica, which are utilized in diagnostics and nanomedicine. The company provides contract research and development services, as well as contract manufacturing, ensuring tailored solutions for their clients. With a focus on high-quality materials and a robust R&D operation, nanoComposix is well-positioned to support advancements in medical devices and drug delivery systems. Their commitment to scientific rigor and quality is underscored by their ISO 13485:2016 certification, which reflects their adherence to stringent quality management standards.


5. RS Research

  • Website: rsresearch.net
  • Ownership type: Corporate
  • Headquarters: Pendik, İstanbul, Turkey
  • Employee distribution: Turkey 100%
  • Latest funding: Other (Grant), $109,000, March 2024
  • Founded year: 2015
  • Headcount: 11-50
  • LinkedIn: rs-research

RS Research is a biotechnology company based in Pendik, İstanbul, Turkey, founded in 2015. The company focuses on developing smart nanomedicines aimed at improving targeted chemotherapy treatments. Their innovative drug delivery technology is designed to enhance the therapeutic index of cancer treatments while reducing side effects, making it a significant player in the oncology field. RS Research's proprietary platform, Sagitta®, allows for the design of targeted drug candidates tailored for various cancer indications. The company has been active in clinical trials, with their lead candidate, RS-0139, currently in Phase I studies. They have also received funding, including a recent grant of approximately $108,734 in March 2024, which supports their ongoing research initiatives. RS Research's commitment to advancing cancer therapies positions them as a noteworthy entity in the nanopharmaceutical industry.


6. ANP Technologies, Inc.

  • Website: anptinc.com
  • Ownership type: Private
  • Headquarters: United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2002
  • Headcount: 11-50
  • LinkedIn: anp-technologies-inc.

ANP Technologies, Inc. is a biotechnology company based in Newark, Delaware, founded in 2002. The firm specializes in creating innovative nano-therapeutics and drug delivery systems, catering primarily to pharmaceutical companies and research institutions. Their product offerings include advanced solutions for immunogenicity testing and biodefense applications. ANP has developed a range of therapies, including nanoencapsulated paclitaxel, which is currently in clinical trials, and an antibody cocktail for Ebola treatment. The company has also partnered with Fulgent Pharma and the Moffitt Cancer Center to develop targeted therapies for leukemia, showcasing their commitment to addressing critical health challenges through nanotechnology. ANP Technologies has achieved ISO 9001:2008 certification, reflecting their dedication to quality management in the development and manufacturing of their products.


7. Mallatt's Pharmacy and Costumes

  • Website: mallatts.com
  • Ownership type: Private
  • Headquarters: Madison, Wisconsin, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 1928
  • Headcount: 51-200
  • LinkedIn: mallatt-pharmacy-and-costumes

Mallatt's Pharmacy and Costumes operates primarily through its biotechnology arm, Co-D Therapeutics. Founded in 1928 and based in Madison, Wisconsin, the company is dedicated to addressing unmet medical needs in cancer therapy. Co-D Therapeutics specializes in the development of combination nanomedicines, with a notable product in their pipeline being Triolimus. This innovative treatment integrates multiple anti-cancer agents into a single delivery system, utilizing polymeric micelle technology to enhance drug delivery to solid tumors. The company is actively seeking strategic partnerships to further develop its nanomedicine programs, indicating a commitment to advancing its research and product offerings in the oncology space.


8. Affilogic

  • Website: affilogic.com
  • Ownership type: Private
  • Headquarters: Nantes, Pays De La Loire, France
  • Employee distribution: France 100%
  • Founded year: 2010
  • Headcount: 11-50
  • LinkedIn: affilogic

Affilogic is a biotechnology firm based in Nantes, France, founded in 2010. The company focuses on the development of Nanofitins, which are small, engineered proteins designed for therapeutic applications. These proteins are particularly notable for their potential in cancer treatment and the oral delivery of biologics, which can enhance patient compliance and reduce side effects. Affilogic collaborates with various pharmaceutical companies and research institutions to innovate in drug development and delivery. Their research includes projects aimed at creating multispecific Nanofitins that target tumor microenvironments and enhance the efficacy of cancer therapies. Additionally, they are exploring the use of Nanofitins for oral delivery systems, which could revolutionize how biologics are administered. Affilogic's commitment to advancing therapeutic solutions positions it as a significant player in the biotechnology and nanopharmaceutical sectors.


9. Abogen Biosciences


Abogen Biosciences, founded in 2019 and based in Suzhou, Jiangsu, China, is a biopharmaceutical company focused on the development of mRNA-based drugs. The company has established a robust platform for mRNA and nano-delivery technologies, particularly lipid nanoparticles (LNPs), which are crucial for effective drug delivery. Abogen is one of the few companies in China with a complete mRNA drug development chain, covering everything from mRNA design to large-scale production. Their product pipeline includes mRNA vaccines for infectious diseases, such as their COVID-19 vaccine, ARCoV (marketed as AWcorna), which was the first mRNA vaccine approved in China. The company has also received substantial funding, including a $300 million Series C round in late 2021, which supports their ongoing research and development efforts in areas like cancer immunotherapy and protein replacement therapies.


10. InnoMedica Holding AG

  • Website: innomedica.com
  • Ownership type: Venture Capital
  • Headquarters: Bern, Bern, Switzerland
  • Employee distribution: Switzerland 96%, Germany 4%
  • Latest funding: $16.2M, November 2021
  • Founded year: 2000
  • Headcount: 51-200
  • LinkedIn: innomedica-ag

InnoMedica Holding AG is a Swiss pharmaceutical company based in Bern, founded in 2000. Initially established as a financial entity, the company transitioned into a fully operational pharmaceutical firm in 2013, focusing on the development of innovative drug delivery systems through nanocarrier technology. InnoMedica aims to create targeted therapies primarily for oncology and neurology, addressing the pressing need for effective treatments that minimize side effects. Their operations include GMP manufacturing and CRDMO services, which cater to both healthcare providers and pharmaceutical companies. The company has developed a proprietary technology platform that allows for the customization of liposomal formulations, enhancing the delivery of therapeutic agents directly to the intended site of action. InnoMedica's product pipeline includes advanced clinical studies for their oncology product TLD-1 and their neurology product TLN-1, which targets neurodegenerative diseases. The company has also expanded its infrastructure and workforce significantly in recent years, reflecting its growth trajectory and commitment to innovation in the pharmaceutical sector.


11. 1Globe Health Institute

  • Website: 1globe-usa.com
  • Ownership type: Private
  • Headquarters: Norwood, Massachusetts, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2012
  • Headcount: 11-50
  • LinkedIn: 1globe-health-institute

1Globe Health Institute, based in Norwood, Massachusetts, is a biotechnology firm founded in 2012. The company specializes in cancer therapeutics and innovative medical technologies, focusing on the discovery, development, and commercialization of targeted therapeutic agents. Their research is driven by a team of scientists who utilize proprietary technologies, including asymmetrical gene-silencing and novel nanotechnology. 1Globe Health Institute is particularly noted for its work in developing drug delivery systems that leverage nanotechnology principles to enhance the efficacy of their therapeutic agents. Their clientele includes pharmaceutical companies and healthcare providers seeking effective solutions for challenging diseases. The company operates in close proximity to the Boston area, a hub for scientific and pharmaceutical innovation, which supports their research and development efforts.


12. OncoNano Medicine, Inc.

  • Website: onconano.com
  • Ownership type: Venture Capital
  • Headquarters: Southlake, Texas, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series B, $18.4M, October 2021
  • Founded year: 2014
  • Headcount: 11-50
  • LinkedIn: onconano-medicine

OncoNano Medicine, Inc. is a biotechnology firm based in Southlake, Texas, founded in 2014. The company specializes in developing innovative cancer treatments using its proprietary ON-BOARD™ nanotechnology platform. This platform is designed to enhance drug delivery specifically to tumor sites, leveraging the unique characteristics of the tumor microenvironment. OncoNano is currently in the clinical stage, with several therapies under development, including ONM-501, a dual-activating STING agonist, and Pegsitacianine, a pH-sensitive fluorescent nanoprobe. The company has been involved in clinical trials to validate its therapies, and it has secured $18.4 million in funding as of October 2021, reflecting strong investor interest in its potential to improve patient outcomes in cancer care.


13. EnGeneIC

  • Website: engeneic.com
  • Ownership type: Venture Capital
  • Headquarters: Lane Cove West, New South Wales, Australia
  • Employee distribution: Australia 100%
  • Latest funding: $150,000, April 2017
  • Founded year: 2001
  • Headcount: 11-50
  • LinkedIn: engeneic

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to the research, development, and manufacturing of targeted anti-cancer therapies through its proprietary EDV™ nanocell platform. This platform is designed to deliver chemotherapeutics and functional nucleic acids directly to tumors, enhancing the immune response while minimizing side effects. EnGeneIC has made significant strides in the healthcare sector, particularly in oncology, and has developed a robust pipeline of clinical trials. The company has also garnered attention for its innovative approaches, receiving recognition for its intellectual property portfolio, which includes over 435 granted patents worldwide. In 2017, EnGeneIC secured funding of $150,000, which supports its ongoing research and development efforts. Their recent achievements, including FDA Fast-Track designation for a pancreatic cancer therapeutic, further underscore their active role in advancing cancer treatment.


14. DIVERSA Technologies


DIVERSA Technologies, founded in 2022 and based in Santiago De Compostela, A Coruña, Spain, is a biotechnology company focused on innovative drug delivery systems. The company specializes in developing nanoparticle formulations designed to enhance the delivery and efficacy of various therapeutic molecules. Their products cater primarily to researchers and pharmaceutical companies, addressing the critical challenge of overcoming biological barriers in drug development. DIVERSA's offerings include a range of nanoparticle solutions for mRNA, proteins, peptides, and small molecules, showcasing their commitment to advancing drug delivery technologies. The company operates with a small team, emphasizing agility and innovation in their approach to drug delivery. DIVERSA Technologies aims to facilitate the transfer of new therapeutic molecules to clinical applications, ultimately improving patient outcomes.


15. ACM Biolabs

  • Website: acmbiolabs.com
  • Ownership type: Venture Capital
  • Headquarters: Singapore
  • Employee distribution: Singapore 100%
  • Latest funding: $6.8M, September 2022
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: acm-biolabs

ACM Biolabs, founded in 2013 and based in Singapore, is a biotechnology firm that specializes in innovative drug delivery systems and therapeutics. The company is focused on developing polymer-based nanoparticle platforms aimed at enhancing vaccine and therapy delivery for various diseases. Their proprietary technology, known as the ACM Tunable Platform (ATP™), allows for the delivery of multiple drug payloads, including oligonucleotides, small molecules, proteins, and mRNA. This platform is notable for its thermostability, enabling mRNA storage at 4°C, which is a significant improvement over traditional lipid nanoparticle systems that require ultra-low temperatures. ACM Biolabs has a growing pipeline of products targeting infectious diseases, respiratory infections, and cancer, with several programs already in clinical trials. The company has received $6.8 million in funding as of September 2022, reflecting its active role in the biotechnology sector and its commitment to addressing unmet medical needs.


16. Peel Therapeutics

  • Website: peeltx.com
  • Ownership type: Venture Capital
  • Headquarters: Salt Lake City, Utah, United States (USA)
  • Employee distribution: Israel 50%, United States (USA) 50%
  • Latest funding: Series A, February 2025
  • Founded year: 2015
  • Headcount: 11-50
  • LinkedIn: peel-therapeutics

Peel Therapeutics, founded in 2015 and based in Salt Lake City, Utah, is a biotechnology firm dedicated to creating innovative medicines inspired by evolutionary biology. The company aims to address significant unmet clinical needs in oncology and immune diseases. Their product offerings include PEEL-224, a PEGylated TOP1 inhibitor designed to treat solid tumors, and EP53 Lipid Nanoparticles, which deliver the elephant p53 tumor suppressor gene. Peel Therapeutics employs a unique approach that combines insights from nature with advanced drug development techniques. Their research and development efforts are bolstered by a proprietary discovery engine called Darwin.AI™, which identifies drug targets based on evolutionary principles. The company operates with a small team of around 17 employees, split between the United States and Israel, and has not reported any recent funding, indicating a focus on internal development and strategic growth.


17. Biotechna S.A.

  • Website: bsbiotechna.com
  • Ownership type: Private
  • Headquarters: Kraków, Lesser Poland Voivodeship, Poland
  • Employee distribution: Poland 100%
  • Founded year: 2019
  • Headcount: 11-50
  • LinkedIn: bs-biotechna

Biotechna S.A., founded in 2019 and based in Kraków, Poland, is a private biotechnology firm dedicated to the development of innovative cancer therapies. The company specializes in targeted therapies that utilize nanotechnology and small interfering RNA (siRNA) technology. Their primary focus is on oncology, where they aim to address significant unmet medical needs. Biotechna's team consists of highly skilled professionals in nanochemistry, biology, and medicine, who are engaged in both preclinical and clinical research. They have developed a proprietary nanoparticle platform designed for the effective delivery of nucleic acids and small molecules, enhancing the precision and efficacy of cancer treatments. The company is actively pursuing new drug synergies and indications for known compounds, with a pipeline that includes over 20 confirmed high-efficacy synergies across various cancer types. Their innovative approach positions them as a notable player in the biotechnology sector, particularly in the field of nanopharmaceuticals.


18. Nanocopoeia

  • Website: nanocopoeia.com
  • Ownership type: Private
  • Headquarters: Saint Paul, Minnesota, United States (USA)
  • Latest funding: Other (Grant), $500,000, September 2006
  • Founded year: 2001
  • Headcount: 11-50
  • LinkedIn: nanocopoeia

Nanocopoeia, founded in 2001 and based in Saint Paul, Minnesota, is a privately held specialty research company dedicated to pharmaceutical development. The company emerged from a technology license with the University of Minnesota and has since focused on solving complex drug formulation challenges, particularly those related to solubility and bioavailability. Their innovative approach includes the use of advanced nano-scale coating processes and proprietary atomization technology, which allows for the creation of macro-scale drug formulation particles with enhanced surface area and uniformity. Nanocopoeia has made significant progress in developing a pipeline of drug products aimed at improving patient safety and compliance. The company has also received funding, including a grant of $500,000 in 2006, which has supported their growth and technological advancements. With a team of experienced professionals in pharmaceutical sciences, Nanocopoeia is well-positioned to collaborate with partners in the industry to create valuable drug products.


19. Genevant Sciences

  • Website: genevant.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 96%, United States (USA) 4%
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: genevant

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company specializes in nucleic acid delivery technologies, focusing on lipid nanoparticles (LNPs) to enhance the delivery of mRNA and siRNA therapies. With a team that boasts decades of experience in nucleic acid drug development, Genevant has established a strong patent estate, holding over 700 patents worldwide. Their technology has been validated through clinical programs involving more than 600 subjects, showcasing their capability in advancing products from the lab to clinical trials. Genevant collaborates with various pharmaceutical and biotechnology companies, aiming to address the challenges of effective nucleic acid delivery and to transform therapeutic approaches in human health.


20. SGN Nanopharma Inc

  • Website: sgnnanopharma.com
  • Ownership type: Private
  • Headquarters: Tampa, Florida, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Founded year: 2010
  • Headcount: 11-50
  • LinkedIn: sgn-nanopharma-inc

SGN Nanopharma Inc., based in Tampa, Florida, is a private pharmaceutical company founded in 2010. The firm specializes in the development of innovative nanomedicines and combination therapies, focusing on chronic diseases that are often inadequately addressed by existing treatments. SGN Nanopharma employs its proprietary Micellar Nanoparticle (MNP) technology to enhance the bioavailability and effectiveness of drugs. The company is currently in the clinical stage, with several products in its pipeline, including treatments for dry eye disease and diabetic neuropathy. SGN has established strategic partnerships to support its development efforts and has received funding for research programs from the Florida HiTech Corridor. Their mission is to deliver impactful, clinically differentiated medicines that improve patient outcomes and reduce healthcare burdens.


21. OxSonics Therapeutics

  • Website: oxsonics.com
  • Ownership type: Venture Capital
  • Headquarters: Oxford, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 100%
  • Latest funding: Series B, $13.1M, July 2020
  • Founded year: 2013
  • Headcount: 11-50
  • LinkedIn: oxsonics-limited

OxSonics Therapeutics, founded in 2013 and based in Oxford, England, is a biotechnology firm dedicated to developing innovative cancer therapies. The company specializes in the SonoTran® platform, which enhances the delivery of anti-cancer drugs to solid tumors, addressing a major limitation in current cancer treatments. Their technology is drug agnostic, meaning it can be applied to both existing and novel therapies without the need for reformulation. OxSonics collaborates with pharmaceutical and biotech companies to optimize cancer therapies, aiming to improve treatment outcomes for patients. The company has received significant funding, with a Series B round totaling over £13 million in July 2020, which supports their ongoing research and development efforts. Their commitment to advancing drug delivery solutions positions them as a notable player in the biotechnology sector.


22. NanoSyrinx

  • Website: nanosyrinx.com
  • Ownership type: Venture Capital
  • Headquarters: Coventry, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 100%
  • Latest funding: Series A, $13.1M, September 2024
  • Founded year: 2019
  • Headcount: 1-10
  • LinkedIn: nanosyrinx

NanoSyrinx is a synthetic biology company based in Coventry, England, founded in 2019. The company specializes in developing a groundbreaking drug delivery platform that utilizes nanosyringes to facilitate targeted intracellular delivery of biologic therapeutics. This innovative approach aims to overcome the challenges associated with delivering complex biologic drugs, such as antibodies and peptides, which often struggle to reach their intended targets within cells. NanoSyrinx's technology is built on over a decade of research from the University of Warwick, where the concept of nanosyringes was first discovered. Recently, the company closed a £10 million financing round, co-led by notable investors including BGF, Octopus Ventures, and Eli Lilly and Company. This funding will support the advancement of their technology platform, which is designed to unlock previously undruggable intracellular targets, thereby addressing significant unmet medical needs. With a small but growing team, NanoSyrinx is actively seeking to expand its capabilities and impact within the pharmaceutical industry.


23. Acuitas Therapeutics

  • Website: acuitastx.com
  • Ownership type: Private
  • Headquarters: Vancouver, British Columbia, Canada
  • Employee distribution: Canada 100%
  • Founded year: 2009
  • Headcount: 51-200
  • LinkedIn: acuitastx

Acuitas Therapeutics, founded in 2009 and based in Vancouver, British Columbia, is a biotechnology company that specializes in the development of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to advance innovative therapies aimed at addressing unmet clinical needs. Acuitas is recognized for its clinically validated LNP technology, which has been instrumental in the development of RNAi therapeutics, such as Onpattro™, approved for treating transthyretin amyloidosis. Additionally, Acuitas played a crucial role in the development of COMIRNATY®, the COVID-19 vaccine by BioNTech and Pfizer, showcasing its capabilities in mRNA therapeutics. The company continues to explore new applications for its LNP technology, including vaccines for infectious diseases and immunomodulation therapies for cancer.


24. Vianautis

  • Website: vianautis.com
  • Ownership type: Venture Capital
  • Headquarters: Cambridge, England, United Kingdom (UK)
  • Employee distribution: United Kingdom (UK) 100%
  • Latest funding: Series A, $24.6M, November 2023
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: vianautis

Vianautis is a biotechnology firm based in Cambridge, UK, founded in 2018 as a spin-off from University College London. The company specializes in the development of genetic nanomedicines, utilizing its proprietary polyNaut® technology. This platform employs advanced polymer materials and machine learning to create targeted drug delivery systems, particularly for challenging conditions affecting the central nervous system and lungs. Vianautis collaborates with pharmaceutical companies and research institutions, providing innovative solutions for genetic therapies. The company has recently raised $25 million in a Series A funding round, which will support its ambitious pipeline of products and further development of its technology. Vianautis operates from state-of-the-art facilities in Cambridge, reflecting its commitment to cutting-edge research and development in the biotechnology field.



Nanopharmaceuticals Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Precision NanoSystems is now part of CytivaVancouver, British Columbia, Canada51-2002010Corporate
Nanovex BiotechnologiesHonduras11-502014Private
Apurano Pharmaceuticals GmbHWarngau, Bavaria, Germany11-502014Private
nanoComposix | Fortis Life SciencesSan Diego, California, United States (USA)51-2002004Private Equity
RS ResearchPendik, İstanbul, Turkey11-502015Corporate
ANP Technologies, Inc.United States (USA)11-502002Private
Mallatt's Pharmacy and CostumesMadison, Wisconsin, United States (USA)51-2001928Private
AffilogicNantes, Pays De La Loire, France11-502010Private
Abogen BiosciencesSuzhou, Jiangsu, China201-5002019Private Equity
InnoMedica Holding AGBern, Bern, Switzerland51-2002000Venture Capital
1Globe Health InstituteNorwood, Massachusetts, United States (USA)11-502012Private
OncoNano Medicine, Inc.Southlake, Texas, United States (USA)11-502014Venture Capital
EnGeneICLane Cove West, New South Wales, Australia11-502001Venture Capital
DIVERSA TechnologiesSantiago De Compostela, A Coruña, Spain1-102022Private
ACM BiolabsSingapore11-502013Venture Capital
Peel TherapeuticsSalt Lake City, Utah, United States (USA)11-502015Venture Capital
Biotechna S.A.Kraków, Lesser Poland Voivodeship, Poland11-502019Private
NanocopoeiaSaint Paul, Minnesota, United States (USA)11-502001Private
Genevant SciencesVancouver, British Columbia, Canada11-502018Private
SGN Nanopharma IncTampa, Florida, United States (USA)11-502010Private
OxSonics TherapeuticsOxford, England, United Kingdom (UK)11-502013Venture Capital
NanoSyrinxCoventry, England, United Kingdom (UK)1-102019Venture Capital
Acuitas TherapeuticsVancouver, British Columbia, Canada51-2002009Private
VianautisCambridge, England, United Kingdom (UK)11-502018Venture Capital


Want to Find More Nanopharmaceuticals Companies?

If you want to find more companies that provide nano-formulations, drug delivery systems, and advanced therapies you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!